Implementation of amotosalen plus ultraviolet A-mediated pathogen reduction for all platelet concentrates in France: Impact on the risk of transfusion-transmitted infections.
pathogen reduction
platelet concentrate
transfusion-transmitted infection
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
28 Dec 2023
28 Dec 2023
Historique:
revised:
14
11
2023
received:
28
09
2023
accepted:
28
11
2023
medline:
28
12
2023
pubmed:
28
12
2023
entrez:
28
12
2023
Statut:
aheadofprint
Résumé
Pathogen reduction (PR) technology may reduce the risk of transfusion-transmitted infections (TTIs), notably transfusion-transmitted bacterial infection (TTBI) associated with platelet concentrates (PCs). PR (amotosalen/UVA treatment) was implemented for all PCs transfused in France in November 2017. No bacterial detection was in place beforehand. The study aimed to assess the impact of PR PC on TTI and TTBI near-miss occurrences. TTI and TTBI near-miss occurrences were compared before and after 100% PR implementation. The study period ran from 2013 to 2022. Over 300,000 PCs were transfused yearly. No PC-related transmission of human immunodeficiency virus, hepatitis C virus, hepatitis B virus and human T-cell lymphotropic virus was reported throughout the study period. PC-mediated hepatitis E virus and hepatitis A virus infections occurred irrespective of PR implementation. Mean PC-mediated TTBI occurrence before PR-PC implementation was 3/year (SD: 1; n = 15; 1/92,687 PC between 2013 and 2016) with a fatal outcome in two patients. Since PR implementation, one TTBI has been reported (day 4 PC, Bacillus cereus) (1/1,645,295 PC between 2018 and 2022; p < 0.001). Two PR PC quarantined because of a negative swirling test harboured bacteria: a day 6 PC in 2021 (B. cereus and Staphylococcus epidermidis) and a day 7 PC in 2022 (Staphylococcus aureus). Five similar occurrences with untreated PC were reported between 2013 and 2020. Transfusion of 100% PR PC resulted in a steep reduction in TTBI occurrence. TTBI may, however, still occur. Pathogen-reduced PC-related TTI involving non-enveloped viruses occurs as well.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Pathogen reduction (PR) technology may reduce the risk of transfusion-transmitted infections (TTIs), notably transfusion-transmitted bacterial infection (TTBI) associated with platelet concentrates (PCs). PR (amotosalen/UVA treatment) was implemented for all PCs transfused in France in November 2017. No bacterial detection was in place beforehand. The study aimed to assess the impact of PR PC on TTI and TTBI near-miss occurrences.
MATERIALS AND METHODS
METHODS
TTI and TTBI near-miss occurrences were compared before and after 100% PR implementation. The study period ran from 2013 to 2022. Over 300,000 PCs were transfused yearly.
RESULTS
RESULTS
No PC-related transmission of human immunodeficiency virus, hepatitis C virus, hepatitis B virus and human T-cell lymphotropic virus was reported throughout the study period. PC-mediated hepatitis E virus and hepatitis A virus infections occurred irrespective of PR implementation. Mean PC-mediated TTBI occurrence before PR-PC implementation was 3/year (SD: 1; n = 15; 1/92,687 PC between 2013 and 2016) with a fatal outcome in two patients. Since PR implementation, one TTBI has been reported (day 4 PC, Bacillus cereus) (1/1,645,295 PC between 2018 and 2022; p < 0.001). Two PR PC quarantined because of a negative swirling test harboured bacteria: a day 6 PC in 2021 (B. cereus and Staphylococcus epidermidis) and a day 7 PC in 2022 (Staphylococcus aureus). Five similar occurrences with untreated PC were reported between 2013 and 2020.
CONCLUSION
CONCLUSIONS
Transfusion of 100% PR PC resulted in a steep reduction in TTBI occurrence. TTBI may, however, still occur. Pathogen-reduced PC-related TTI involving non-enveloped viruses occurs as well.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 International Society of Blood Transfusion.
Références
Prowse CV. Component pathogen inactivation. A critical review. Vox Sang. 2013;104:183-199.
Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system™. Transfus Med Hemother. 2011;38:19-31.
Schmidt M, Hourfar MK, Sireis W, Pfeiffer U, Göttig S, Kempf VAJ, et al. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains: efficiency of pathogen inactivation. Transfusion. 2015;55:2104-2112.
Benjamin RJ, Braschler T, Weingand T, Corash LM. Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems. Transfusion. 2017;57:2946-2957.
Le Cam S, Houze S, Barlet V, Maugard C, Narboux C, Morel P, et al. Preventing transfusion-transmitted malaria in France. Vox Sang. 2021;116:943-945.
Lafeuillade B, Eb F, Ounnoughene N, Petermann R, Daurat G, Huyghe G, et al. Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008. Transfusion. 2015;55:636-646.
Cappy P, Barlet V, Lucas Q, Tinard X, Pillonel J, Gross S, et al. Transfusion of HIV-infected blood products despite highly sensitive nucleic acid testing. Transfusion. 2019;59:2046-2053.
Gallian P, Barlet V, Mouna L, Gross S, Lecam S, Ricard C, et al. Hepatitis A: an epidemiological survey in blood donors, France 2015 to 2017. Euro Surveill. 2018;23:1800237.
Gallian P, Barlet V, Mouna L, Gross S, Morel P, Le Cam S, et al. Persisting higher prevalence of hepatitis A virus RNA in blood donors, France, 2018. Euro Surveill. 2019;24:1900695.
Lefeuvre C, Lefort C, Boyer F, Le Cam S, Mouna L, Roque-Afonso AM, et al. Transfusion-transmitted hepatitis A virus, France, 2018. Emerg Infect Dis. 2022;28:219-223.
Hauser L, Menasie S, Bonacorsi S, Raoult L, AitOubelli N, Belloy M, et al. Fatal transfusion-transmitted infection due to Citrobacter koseri. Transfusion. 2016;56:1311-1313.
Gallian P, Cabié A, Richard P, Paturel L, Charrel RN, Pastorino B, et al. Zika virus in asymptomatic blood donors in Martinique. Blood. 2017;129:263-266.
Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019;133:1854-1864.
Giménez-Richarte Á, Ortiz de Salazar MI, Giménez-Richarte MP, Larrea L, Arbona C, Marco P, et al. Pathogen inactivation methods to prevent transfusion-transmissible arboviruses: a systematic review and meta-analysis. Trop Med Int Health. 2023;28:262-274.
Stramer SL, Lanteri MC, Brodsky JP, Foster GA, Krysztof DE, Groves JA, et al. Mitigating the risk of transfusion-transmitted infections with vector-borne agents solely by means of pathogen reduction. Transfusion. 2022;62:1388-1398.
Hauser L, Roque-Afonso AM, Beylouné A, Simonet M, Deau Fischer B, Burin des Roziers N, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood. 2014;123:796-797.
Gallian P, Lhomme S, Morel P, Gross S, Mantovani C, Hauser L, et al. Risk for hepatitis E virus transmission by solvent/detergent-treated plasma. Emerg Infect Dis. 2020;26:2881-2886.
Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, et al. Photochemical treatment of plasma with amotosalen and long-wave length ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion. 2006;46:1168-1177.
Störmer M, Vollmer T. Diagnostic methods for platelet bacteria screening: current status and developments. Transfus Med Hemother. 2014;41:19-27.
McDonald C, Allen J, Brailsford S, Roy A, Ball J, Moule R, et al. Bacterial screening of platelet components by National Health Service Blood and Transplant, an effective risk reduction measure. Transfusion. 2017;57:1122-1131.
Annual SHOT report 2022. Available from: https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2022-FINAL-Bookmarked-1.pdf. Accessed 12 Sep 2023.
Wagner SJ, Dy B, Young P, Goldberg C, Mair D, Fadeyi E, et al. Septic risk increases with apheresis platelet storage time. Transfusion. 2020;60:220-222.
Kracalik I, Kent AG, Villa CH, Gable P, Annambhotla P, McAllister G, et al. Posttransfusion sepsis attributable to bacterial contamination in platelet collection set manufacturing facility, United States. Emerg Infect Dis. 2023;29:1979-1989.
Störmer M, Vollmer T, Kleesiek K, Dreier J. Spore-forming organisms in platelet concentrates: a challenge in transfusion bacterial safety. Transfus Med. 2008;18:371-376.
Fadeyi EA, Wagner SJ, Goldberg C, Lu T, Young P, Bringmann PW, et al. Fatal sepsis associated with a storage container leak permitting platelet contamination with environmental bacteria after pathogen reduction. Transfusion. 2021;61:641-648.
Cloutier M, De Korte D, ISBT Transfusion-Transmitted Infectious Diseases Working Party, Subgroup on Bacteria. Residual risks of bacterial contamination for pathogen-reduced platelet components. Vox Sang. 2022;117:879-886.
Green AB, Chiaraviglio L, Truelson KA, Zulauf KE, Cui M, Zhang Z, et al. RND pump-mediated efflux of amotosalen, a compound used in pathogen inactivation technology to enhance safety of blood transfusion products, may compromise its Gram-negative anti-bacterial activity. mSphere. 2023;8:e0067322.
Chi SI, Yousuf B, Paredes C, Bearne J, McDonald C, Ramirez-Arcos S. Proof of concept for detection of staphylococcal enterotoxins in platelet concentrates as a novel safety mitigation strategy. Vox Sang. 2023;118:543-550.